This kit is an ELISA assay capable of highly sensitive measurement of the novel blood biomarker Mid‑pTau181 in the field of dementia research.
Mid‑pTau181 is a new dementia blood biomarker discovered by Professor Tokuda of Osaka Metropolitan University, reflecting tau pathology and providing an additional axis of evaluation alongside existing tau‑related markers.
 

The greatest strength of Mid‑pTau181 lies in its potential to improve diagnostic accuracy when used in combination with pTau217.
Its significance is not limited to standalone measurement. It demonstrates value within integrated assessments that combine multiple biomarkers.
This allows researchers and developers to establish an environment that supports:

• More precise evaluation of disease pathology
• Multifaceted biomarker analysis
•  Advancement of dementia diagnostic research
   

We offer the world’s first ELISA kit capable of measuring Mid‑pTau181.
This represents not merely an expansion of our product lineup, but a clearly differentiated and leading market position.
 

Mid‑pTau181 generates higher added value when used together with existing tau markers such as pTau217.
Within our ATN strategy, it plays a key role not as a standalone marker, but as part of an integrated multi‑marker measurement platform.
 

The Mid‑pTau181 ELISA Kit offers not only scientific novelty for research use, but also substantial business value.
It supports:

• Demonstration of technological leadership in the research market
• Establishment of competitive advantage through high‑value biomarkers
• Strengthening of a differentiated model integrating instruments and dedicated reagents

Through this product, we aim to build a business structure chosen for its uniqueness and diagnostic value rather than price competition.
 

Mid‑pTau181 is a strategic product that most clearly demonstrates our differentiation from competitors within our biomarker business.
While pTau217 serves as a mainstream marker with broad market potential, Mid‑pTau181 represents our unique strength, showcasing technological advancement and a distinct market position to researchers, pharmaceutical companies, and investors.